Bifogade filer
20241119_Isofol_Nomination Committee_Final
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
GOTHENBURG, Sweden, November 19, 2024 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol” or the ”Company”), announced today that the members of the nomination committee for the Annual General Meeting 2025 have been appointed in accordance with the principles for appointing nomination committees that were adopted at the Annual General Meeting 2024.
The information in the press release is intended for investors.
According to the instructions for appointment of the nomination committee for Isofol, the nomination committee shall consist of three members appointed by the three largest shareholders in the company, based on the number of votes in the share register provided by Euroclear Sweden AB or other reliable information as of September 30, 2024. Another nomination committee member may be appointed by minority shareholders representing at least 10 percent of the votes based on the share register provided by Euroclear Sweden AB or other reliable information. The chairman of the nomination committee shall consist of the largest shareholder in terms of votes at the time of the nomination committee's appearance, unless the nomination committee agrees otherwise, and may not consist of the chairman of the board or another board member. The chairman of the board shall not be part of the nomination committee but is normally a co-opted member at its meetings.
The nomination committee ahead of the AGM 2025 consists of the following members:
- Christian Haglund, representing approximately 4.73 percent of the shares and votes
- Göran Gustafsson, representing approximately 3.74 percent of the shares and votes,
- Johan Möller, chairman of the nomination committee, appointed by Mats Franzén representing approximately 3.69 percent of the shares and votes, and
- Lars Lind, appointed by a minority of owners representing 16.80 percent of shares and votes.
The members of the nomination committee are appointed by owners who represent a total of 28.96 percent of the total number of shares and votes in Isofol according to the ownership conditions as of September 30, 2024.
Information about the nomination committee’s work and the instructions to the nomination committee can be found on the company website under the section for Corporate Governance. The nomination committee’s proposal will be presented in the summons to the annual general meeting 2025 and on the company’s website, www.isofolmedical.com.
Shareholders who wish to submit proposals to the nomination committee shall do this in writing by sending an e-mail to valberedningen@isofolmedical.com (heading: "Isofol's nomination committee") or by mail to the following address:
Isofol Medical AB (publ)
Att. Valberedningen
Arvid Wallgrens Backe 20
413 46 GOTHENBURG
SWEDEN
Any proposals must be received by the nomination committee no later than February 28, 2025, to be included in the notice and agenda for the Annual General Meeting 2025.
The Annual General Meeting in Isofol Medical AB (publ) will be held on May 21, 2025, in Gothenburg.
For more information, please contact
Jan-Eric Österlund, Chairman of the board
E-mail: jan-eric.osterlund@isofolmedical.com
Phone: +44 7785 368 155
Isofol Medical AB (publ)
Petter Segelman Lindqvist, Chief Executive Officer
E-mail: petter.s.lindqvist@isofolmedical.com
Phone: +46 (0)739 60 12 56
The information was submitted for publication, through the agency of the contact person set out above, at 15:40 CET, on November 19, 2024.
About Isofol Medical AB (publ)
Isofol Medical AB (publ) aims to raise the quality of life and increase the survival rate for patients with severe forms of cancer. The company’s drug candidate arfolitixorin is being developed with the purpose of increasing the efficacy of standard first-line treatment for several forms of solid tumours, including colorectal cancer. The next step in the clinical development program is currently being prepared based on a new dosage regimen that is expected to optimize arfolitixorin’s efficacy. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.